CEO and Founder
GelSana
GelSana Therapeutics develops highly elastic wound dressings using proprietary polymer chemistry that conform to various wound types, reducing inflammation and preventing infection. These dressings also enable sustained drug delivery, addressing the challenges of chronic wound healing.
- Biotechnology
Updated 1 month ago
Funding
Raised to date
$7.9MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
$250K across 1 disclosed round
MV$250K · Seed
Announced Feb 2024 · from article date
Disclosed cumulative: $250K
2/2
Reported total $7.9M
Incomplete round history. $7.7M of the $7.9M reported total isn’t matched to a known round (1 known round has an undisclosed amount).
RoundDateAmountValuationInvestors
Founders
Product
Problem
Chronic wounds and other injuries often require dressings that can conform to complex shapes and maintain consistent contact, but many current options lack sufficient elasticity and drug-delivery capabilities. This can lead to inflammation, infection, and delayed healing, particularly in wounds that are difficult to bandage.
Solution
GelSana Therapeutics develops highly elastic wound dressings using proprietary polymer chemistry, enabling them to stretch and conform to various wound types. These dressings reduce inflammation, prevent infection, and facilitate sustained drug delivery directly to the wound site. By addressing key challenges in wound management, GelSana's technology promotes improved healing outcomes, especially for chronic wounds.
Target Audience
The primary target audience includes healthcare providers, hospitals, and wound-care specialists focused on treating chronic wounds and other injuries requiring advanced dressing materials.
Features
- Highly elastic material that conforms to complex wound shapes
- Proprietary polymer chemistry designed to reduce inflammation
- Integrated antimicrobial properties to prevent infection
- Sustained drug-delivery capabilities for targeted treatment